The WEE1 inhibitor, adavosertib, was studied as a single-agent or combined with olaparib in women with PARP-inhibitor resistant ovarian cancer in the phase II non-comparative EFFORT trial. This evidence concerns the gene PARP1 and ovarian carcinoma.